Degree of Throat Deposition Can Explain the Variability in Lung Deposition of Inhaled Drugs
- 1 December 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Aerosol Medicine
- Vol. 19 (4), 473-483
- https://doi.org/10.1089/jam.2006.19.473
Abstract
Inhalation is a mainstay for treatment of asthma, and lung deposition can be seen as a surrogate marker for the ensuing clinical effects. Not only absolute lung deposition, but also its variability is of interest, as it indicates the range of expected lung deposition in an individual patient when prescribing the drug and the expected day-to-day variability when using it. A literature survey found 71 studies with relevant information on lung deposition and its variability. Further characteristics of the studies, such as if the subjects were healthy or asthmatics, adults or children, and what device that was used, were noted. In all, 187 data points were included. Variability in lung deposition was depicted as a function of mean lung deposition; for the entire data set and for subsets thereof. Independent of device type or subject category high lung deposition was associated with low relative variability and vice versa. Using a published throat deposition model, the observed correlation of lung deposition variability to mean lung deposition could be explained as being determined largely by the extent of and variability in throat deposition. We hypothesize that throat deposition is the major determinant for lung deposition of an inhaled aerosol, and its absolute variability will largely be determined by the absolute variability in throat deposition. The relative variability in lung deposition will therefore tend to be high for low lung deposition and low for high lung deposition. Consequently, low relative variability in lung deposition can only be attained if high lung deposition is achieved.Keywords
This publication has 14 references indexed in Scilit:
- Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler®International Journal of Pharmaceutics, 1999
- LUNG DEPOSITION AND EXTREMELY SLOW INHALATIONS OF PARTICLES. LIMITED EFFECT OF INDUCED AIRWAY OBSTRUCTIONExperimental Lung Research, 1999
- Lung deposition of budesonide from turbuhaler in asthmatic children.European Journal of Pediatrics, 1998
- Mouth and Oropharyngeal Deposition of Pharmaceutical AerosolsJournal of Aerosol Medicine, 1998
- Lung deposition from the Turbuhaler in children with cystic fibrosisEuropean Respiratory Journal, 1997
- The inhalation device influences lung deposition and bronchodilating effect of terbutaline.American Journal of Respiratory and Critical Care Medicine, 1996
- WORKPLACE ASSESSMENTAnnals of Work Exposures and Health, 1994
- Smoke inhalation with a concurrent systemic stress results in lung alveolar injury.American Journal of Respiratory and Critical Care Medicine, 1994
- Importance of the inhalation device on the effect of budesonide.Archives of Disease in Childhood, 1993
- Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.Thorax, 1991